Tocilizumab in Patients With Giant Cell Arteritis: Results From a Phase 3 Randomized Controlled Trial (video)

Identifier	20170403_nanos_sciplatform1_01-video
Title	Tocilizumab in Patients With Giant Cell Arteritis: Results From a Phase 3 Randomized Controlled Trial (video)
Creator	Susan Mollan; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Neil Collinson; John Stone
Affiliation	(SM) University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham B15 2GW, United Kingdom; (KT) (SD) (NC) Roche Products Ltd., Welwyn Garden City, United Kingdom; (MK) Genentech, South San Francisco, California; (JS) Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, Massachusetts
Subject	Vascular Disorders; Neuro-ophth & Systyemic Disease (eg. MS, MG, Thyroid); Optic neuropathy
Description	The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized, double-blind, placebo-controlled trial.1 Data for week 52 outcome measures are presented.
Date	2017
Language	eng
Format	video/mp4
Type	Image/MovingImage
Source	2017 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of	NANOS Annual Meeting 2017: Scientific Platform I
Collection	Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher	North American Neuro-Ophthalmology Society
Holding Institution	Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management	Copyright 2013. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK	ark:/87278/s6gj3crx
Setname	ehsl_novel_nam
ID	1277729
Reference URL	https://collections.lib.utah.edu/ark:/87278/s6gj3crx

Back to Search Results